PT - JOURNAL ARTICLE AU - Trombetta, Bianca A. AU - Kandigian, Savannah E. AU - Kitchen, Robert R. AU - Grauwet, Korneel AU - Kivisäkk Webb, Pia AU - Miller, Glenn A. AU - Jennings, Charles G. AU - Jain, Sejal AU - Miller, Samara AU - Kuo, Yikai AU - Sweeney, Thadryan AU - Gilboa, Tal AU - Norman, Maia AU - Simmons, Daimon P. AU - Ramirez, Christopher E. AU - Bedard, Melissa AU - Fink, Catherine AU - Ko, Jina AU - De León Peralta, Esmarline J. AU - Watts, Gerald AU - Gomez-Rivas, Emma AU - Davis, Vannessa AU - Barilla, Rocky AU - Wang, Jianing AU - Cunin, Pierre AU - Bates, Samuel AU - Morrison-Smith, Chevaun AU - Nicholson, Benjamin AU - Wong, Edmond AU - El-Mufti, Leena AU - Kann, Michael AU - Bolling, Anna AU - Fortin, Brooke AU - Ventresca, Hayden AU - Zhou, Wen AU - Pardo, Santiago AU - Kwock, Megan AU - Hazra, Aditi AU - Cheng, Leo AU - Ahmad, Q. Rushdy AU - Toombs, James A. AU - Larson, Rebecca AU - Pleskow, Haley AU - Luo, Nell Meosky AU - Samaha, Christina AU - Pandya, Unnati M. AU - De Silva, Pushpamali AU - Zhou, Sally AU - Ganhadeiro, Zakary AU - Yohannes, Sara AU - Gay, Rakiesha AU - Slavik, Jacqueline AU - Mukerji, Shibani S. AU - Jarolim, Petr AU - Walt, David R. AU - Carlyle, Becky C. AU - Ritterhouse, Lauren L. AU - Suliman, Sara TI - Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2 AID - 10.1101/2021.01.02.20248998 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.02.20248998 4099 - http://medrxiv.org/content/early/2021/01/04/2021.01.02.20248998.short 4100 - http://medrxiv.org/content/early/2021/01/04/2021.01.02.20248998.full AB - Background COVID-19 has resulted in significant morbidity and mortality worldwide. Lateral flow assays can detect anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) antibodies to monitor transmission. However, standardized evaluation of their accuracy and tools to aid in interpreting results are needed.Methods We evaluated 20 IgG and IgM assays selected from available tests in April 2020. We evaluated the assays’ performance using 56 pre-pandemic negative and 56 SARS-CoV-2-positive plasma samples, collected 10-40 days after symptom onset, confirmed by a molecular test and analyzed by an ultra-sensitive immunoassay. Finally, we developed a user-friendly web app to extrapolate the positive predictive values based on their accuracy and local prevalence.Results Combined IgG+IgM sensitivities ranged from 33.9% to 94.6%, while combined specificities ranged from 92.6% to 100%. The highest sensitivities were detected in Lumiquick for IgG (98.2%), BioHit for both IgM (96.4%), and combined IgG+IgM sensitivity (94.6%). Furthermore, 11 LFAs and 8 LFAs showed perfect specificity for IgG and IgM, respectively, with 15 LFAs showing perfect combined IgG+IgM specificity. Lumiquick had the lowest estimated limit-of-detection (LOD) (0.1 μg/mL), followed by a similar LOD of 1.5 μg/mL for CareHealth, Cellex, KHB, and Vivachek.Conclusion We provide a public resource of the accuracy of select lateral flow assays with potential for home testing. The cost-effectiveness, scalable manufacturing process, and suitability for self-testing makes LFAs an attractive option for monitoring disease prevalence and assessing vaccine responsiveness. Our web tool provides an easy-to-use interface to demonstrate the impact of prevalence and test accuracy on the positive predictive values.Competing Interest StatementD.R.W. has a financial interest in Quanterix Corporation, a company that develops an ultra-sensitive digital immunoassay platform. He is an inventor of the Simoa technology and a founder of the company and also serves on its Board of Directors. D.R.W.s interests were reviewed and are managed by Brigham and Womens Hospital and Partners HealthCare in accordance with their policies on competing interests. The assays in this publication have been licensed by Brigham and Womens Hospital to Quanterix Corporation. M.N., T.G. and D.R.W. have filed intellectual property on the technology described in this manuscript.Clinical TrialThe study used biobanked samples to evaluate serological tests for COVID-19. We did not apply any intervention to the study participants.Funding StatementThe study is supported by funding from the Massachusetts Consortium on Pathogen Readiness (MassCPR)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved under the Massachusetts General Brigham (MGB) Institutional Review Board (protocol no. 2020P001204)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll evaluation data are available in a public repository: https://covidinnovation.partners.org/evaluation/ Web app to generate positive predictive values is available online: https://covid.omics.kitchen. https://covidinnovation.partners.org/evaluation/ https://covid.omics.kitchen